Single-tracer Multiparametric PET Imaging

单示踪剂多参数 PET 成像

• 批准号: 10706613
• 负责人: Guobao Wang
• 金额: $ 62.03万
• 依托单位: UNIVERSITY OF CALIFORNIA AT DAVIS
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-19 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10706613
• 关键词: Address; Alzheimer' s Disease; Ammonia; Applications Grants; Blood; Blood Glucose; Blood flow; Brain; Butanols; Chlorides; Clinic; Clinical; Clinical Research; Coupling; Cyclotrons; Data; Development; Disease; FDA approved; Glucose; Goals; Half-Life; Heart Diseases; Hour; Image; Intravenous; Knowledge; Length; Malignant Neoplasms; Measures; Metabolic; Metabolism; Methods; Modeling; Myocardial; Myocardium; Neurodegenerative Disorders; Noise; Organ; Patients; Physiological Processes; Physiology; Pilot Projects; Positron-Emission Tomography; Process; Protocols documentation; Proxy; Radiation Dose Unit; Research; Scanning; Site; System; Techniques; Time; Tissues; Tracer; Tumor Angiogenesis; Work; cancer therapy; cellular imaging; clinical application; clinical care; cost; detection sensitivity; fluorodeoxyglucose; fluorodeoxyglucose positron emission tomography; glucose metabolism; glucose transport; image reconstruction; imaging biomarker; improved; ischemic cardiomyopathy; kernel methods; kinetic model; metabolic imaging; multiparametric imaging; perfusion imaging; photon-counting detector; public health relevance; radiotracer; temporal measurement; tumor; tumor metabolism; whole body imaging

PROJECT SUMMARY Blood flow and cellular metabolism are two basic but vital physiological processes that are often dysregulated in major diseases. Imaging of flow-metabolism mismatch or coupling is of broad clinical and research significance in many diseases, for instance, in ischemic cardiomyopathy for assessing myocardial viability, in cancer for grading tumor aggressiveness, and in neurodegenerative diseases for studying brain function. A major challenge in PET imaging of flow-metabolism is that scanning for these two processes requires two different radiotracers–18F-fluorodeoxyglucose (FDG) for metabolism and a second flow radiotracer for perfusion imaging. While FDG is widely available in the clinic for metabolic imaging, perfusion imaging by PET is clinically limited, resulting in underutilization of flow-metabolism imaging in both research and clinics. The goal of this project is to develop a single-tracer multiparametric PET imaging solution for simultaneous flow- metabolism imaging using only 18F-FDG without the need for a second flow-specific radiotracer. Early attempts from others and our group have used FDG blood-to-tissue delivery rate (K1) as a proxy of blood flow. However, the accuracy of FDG K1 approximating blood flow largely depends on the FDG extraction fraction in tissues and is also compromised by the correlation between FDG K1 and blood glucose levels. Our preliminary work has tackled these problems specifically in the myocardium and demonstrated the feasibility of using FDG for measuring myocardial blood flow. The focus of this proposal is to extend the effort to a large study and to the whole body, and further develop the enabling techniques to improve FDG blood flow quantification. We will (1) develop glucose-normalized extraction fraction correction for FDG blood flow quantification in various organs using total-body dynamic PET; (2) develop high-temporal resolution kinetic modeling for improved FDG blood flow quantification; (3) improve FDG blood flow imaging on short PET scanners using advanced image reconstruction. Successful completion of this project will develop a new technical capability of 18F-FDG for simultaneous multiparametric imaging of blood flow and glucose metabolism with reduced radiation dose, imaging time and cost. This would also open up many new opportunities for clinical applications that require multiparametric imaging biomarkers but have been historically restricted by the accessibility of perfusion imaging, thus making a broad impact in multiple PET applications for patient clinical care and research.

项目概要 血流和细胞代谢是两个基本但重要的生理过程，经常失调 血流代谢不匹配或耦合的成像具有广泛的临床和研究意义。 在许多疾病中具有重要意义，例如，在缺血性心肌病中评估心肌活力、 在癌症中用于对肿瘤侵袭性进行分级，在神经退行性疾病中用于研究大脑功能。 血流代谢 PET 成像的主要挑战是扫描这两个过程需要两个 不同的放射性示踪剂——用于代谢的 18F-氟脱氧葡萄糖 (FDG) 和用于代谢的第二流放射性示踪剂 FDG 在临床上广泛用于代谢成像，而 PET 灌注成像。 临床上受到限制，导致血流代谢成像在研究和临床中均未得到充分利用。 该项目的目标是开发一种单示踪剂多参数 PET 成像解决方案，用于同时流动- 仅使用 18F-FDG 进行代谢成像，无需第二个血流特异性放射性示踪剂。 其他人和我们小组使用 FDG 血液到组织输送率 (K1) 作为血流量的指标。 FDG K1 近似血流的准确性很大程度上取决于组织中 FDG 的提取分数 并且还受到 FDG K1 和血糖水平之间的相关性的影响。 专门解决了心肌中的这些问题，并证明了使用 FDG 进行治疗的可行性 该提案的重点是将工作扩展到大型研究和 全身，并进一步开发改善 FDG 血流定量的技术。我们将 (1) 开发用于各种器官 FDG 血流定量的葡萄糖归一化提取分数校正 使用全身动态 PET；(2) 开发改进 FDG 血液的高时间分辨率动力学模型 (3) 使用先进的图像改进短 PET 扫描仪上的 FDG 血流成像 该项目的成功完成将为18F-FDG的新技术能力的开发奠定基础。 在减少辐射剂量的情况下对血流和葡萄糖代谢进行同步多参数成像， 这也将为需要的临床应用带来许多新的机会。 多参数成像生物标志物，但历史上一直受到灌注可及性的限制 成像，从而对患者临床护理和研究的多种 PET 应用产生广泛影响。

项目成果

Super-resolution reconstruction of <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mstyle><mml:mstyle><mml:mi>γ</mml:mi></mml:mstyle></mml:mstyle></mml:math>-ray CT images for PET-enabled dual-energy CT imaging.

<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mstyle><mml:mstyle><mml:mi>γ</mml 的超分辨率重建

• DOI: 10.1117/12.2654431
• 发表时间: 2024
• 期刊: Proceedings of SPIE--the International Society for Optical Engineering
• 作者: Zhu,Yansong;Spencer,BenjaminA;Xie,Zhaoheng;Leung,EdwinK;Bayerlein,Reimund;Omidvari,Negar;Cherry,SimonR;Qi,Jinyi;Badawi,RamseyD;Wang,Guobao
• 通讯作者: Wang,Guobao